PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för 2-methoxy-17beta-estradiol. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

9 hits

Bibliografisk träff 2010-10-20

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.

Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS.

Cancer Chemother Pharmacol · clinical trial, phase ii; research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s00280-010-1478-7

Bibliografisk träff 2010-05-25

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G.

Invest New Drugs · clinical trial, phase ii; research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s10637-010-9455-x

Bibliografisk träff 2009-07-04

Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.

Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C, Sidor C.

Gynecol Oncol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1016/j.ygyno.2009.05.042

Bibliografisk träff 2009-02-01

Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies.

Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G.

Clin Cancer Res · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-08-1599

Bibliografisk träff 2008-06-01

Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.

LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, Treston AM.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-08-0107

Bibliografisk träff 2006-09-13

Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.

James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, Miller KD.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10637-006-9008-5

Bibliografisk träff 2006-07-07

Antiangiogenic effect of oral 2-methoxyestradiol on choroidal neovascularization in mice.

Funakoshi T, Birsner AE, D'Amato RJ.

Exp Eye Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.exer.2006.05.016

Bibliografisk träff 2003-01-01

2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway.

LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS.

Cancer Res · journal article

Bibliografisk träff 1996-12-01

17beta-Estradiol metabolites affect some regulators of the MCF-7 cell cycle.

Lottering ML, de Kock M, Viljoen TC, Grobler CJ, Seegers JC.

Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/s0304-3835(96)04489-8